Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies



Rating:

Share or cite this content

Citations should be made in the following way:
M. Farnik (Katowice, Poland), K. Zawada-Drozd (Katowice, Poland), A. Barczyk (Katowice, Poland). Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab. 882

Member's Comments

No comment yet.

Related content which might interest you: Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Severe asthma outcomes over two years of therapy with mepolizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Stepping-down inhaled corticosteroid therapy in stable asthma: a secondary care perspective Source: Eur Respir J 2005; 26: Suppl. 49, 277s Year: 2005 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018 Year: 2018 The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Biologic therapies in paediatric severe asthma Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma Year: 2020